Cited in | Search | Type: | Patent literature | Publication No.: | WO2016011208
[I] (PROTAGONIST THERAPEUTICS INC [US], et al) [I] 1-15 * page 177 - page 219; tables 3-8 * * sequences 1-1029 * * page 196; sequence 645 *; | Type: | Patent literature | Publication No.: | WO2017011820
[AP] (PROTAGONIST THERAPEUTICS INC [US], et al) [AP] 1-15 * sequences 1-1256 * * tables E3A-E34 ** page 196; sequence 645 *; | Type: | Non-patent literature | Publication information: | [A] - CHRISTIANE QUINIOU ET AL, "Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response", AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY , INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, US, (20141115), vol. 307, no. 10, doi:10.1152/ajpregu.00540.2013, ISSN 0363-6119, pages R1216 - R1230, XP055721662 [A] 1-15 * page 1217; figure 1 * * page 1219, column r, paragraph 5 - page 1220, column l, paragraph 1 * | DOI: | http://dx.doi.org/10.1152/ajpregu.00540.2013 | Type: | Non-patent literature | Publication information: | [A] - MILAN KUCHAR ET AL, "Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells", PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, (20131101), doi:10.1002/prot.24472, ISSN 0887-3585, pages n/a - n/a, XP055109904 [A] 1-15 * abstract * * page 2; figure 1 * * page 9; table 1 * | DOI: | http://dx.doi.org/10.1002/prot.24472 | Cited in | International search | Type: | Patent literature | Publication No.: | US2003166138
[A] (KINSELLA TODD [US], et al) [A] 1-2, 9/1-2, 10/9/1-2, 12-13 14/12-13 * ; claim 1 *; | Type: | Patent literature | Publication No.: | WO2016011208
[A] (PROTAGONIST THERAPEUTICS INC [US], et al) [A] 1-2, 9/1-2, 10/9/1-2, 12-13 14/12-13 * ; paragraphs [0010], [0011], [0013] *; | Type: | Patent literature | Publication No.: | US2016039878
[A] (GALLAGHER GRANT [US], et al) [A] 1-2, 9/1-2, 10/9/1-2, 12-13 14/12-13 * ; abstract *; | Type: | Patent literature | Publication No.: | WO2017011820
[PY] (PROTAGONIST THERAPEUTICS INC [US], et al) [PY] 1-2, 9/1-2, 10/9/1-2, 12-13 14/12-13* ; entire document * |